December 1, 2010
11:30 am to 1:00 pm EST
Instructor
James Samanen, Ph.D. President, James Samanen Consulting; formerly worked at GlaxoSmithKline for 31 years
Discussion Topics
Definitions - project vs. program, leader vs. manager, matrix manager (quick reminder)
Pressures on Profitability - how project leaders & portfolio managers can help to keep costs down
Aggregate Project Risk - Why Discovery Resource is managed through line departments, not through project teams as we find in late stage Development
The triangular relationship between line departments, project leaders and portfolio management, focused on project teams
The Perception of Authority – Making it Enough
What is Expected of a Good Project Leader
Getting the Most out of your Team Reps
Maximizing your relationships with Stakeholders and the Bosses of your Team Reps
Who Should Attend
Line managers who intend to move into project management
Project leaders (PLs) who have recently taken on the task
The focus is on Drug Discovery but PLs in Development will benefit as well
Portfolio managers face many of the same issues
Line managers – they use the skills of project leaders
Instructor Biography
James is a pharmaceutical consultant with a track record of 30+ years leadership and innovation in drug discovery project & portfolio management, and portfolio data analysis at GlaxoSmithKline. While at GSK James developed and implemented worldwide Portfolio Management for GlaxoSmithKline Discovery and Genetics Research businesses encompassing 2000 staff and $400M budget - involving negotiation and implementation of processes for selection and prioritization of research programs, developing IT systems, mirroring past to present performance with fit-for-purpose benchmarking analysis, modelling future performance, change management and team training. His work eenabled an increase in productivity of drug-like leads in GSK by > 50% in 2 years by cross-functional team-working, prioritization and 40% portfolio downsizing. He also enabled strategy changes reducing cycle times by 50%. As a group leader in Medicinal Chemistry he ddiscovered & championed lotrafiban (antithrombotic) to Phase III, and 2 preclinical candidate antithrombotics. He has been a project leader in diverse areas of drug discovery. He established James Samanen Consulting in December, 2008.